FDA approves Noor and Nordmen winter insulin injection Fiasp100u/mL label expansion
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Novo Nordisk announced that it has approved the expansion of its fiasp100u/mL labelthe fda's(http://The label extension allows Fiasp to be given through an insulin pump to improve blood sugar control in adults with type 1 and type 2 diabetesThis label extension is based primarily on the FDA's review of thedata for the o
nSET 5 ClinicalTrial(http://This test confirmed that Fiasp, which is drugged by insulin pump, has high safety and efficacyFiasp can be released steadily through an insulin pump and patients show good tolerance indrug(http://doseAbout Fiasp
Fiasp is a quick-acting insulin injection that was approved by the FDA in 2017 Fiasp is a quick-acting insulin injection that is free of pre-meal administration recommendations, and patients can do it before or after meals Fiasp, available in a variety of doses, is a new formulation of NovoRapid, a winter insulin injection for NovoRapid Fiasp adds 2 new excipients that increase the absorption rate of vitamin B3 and increase the stability of L-arginine, ensuring that the drug is faster and better absorbed by the body
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
